1,4-Dioxane → HCID 57917324, compound

HRID 69307Notes

Reaction equation

HRID 69307 reaction equation
[N:1]1[CH:2]=[CH:3][N:4]2[CH:9]=[C:8]([CH:10]([C:12]3[N:16]4[N:17]=[C:18]([C:21]5[CH:22]=[N:23][N:24]([CH2:26][CH2:27][O:28]C6CCCCO6)[CH:25]=5)[CH:19]=[CH:20][C:15]4=[N:14][CH:13]=3)[CH3:11])[CH:7]=[CH:6][C:5]=12.C1C(=O)N([Br:42])C(=O)C1.O1CCOCC1>C(Cl)Cl.Cl>[Br:42][C:3]1[N:4]2[CH:9]=[C:8]([CH:10]([C:12]3[N:16]4[N:17]=[C:18]([C:21]5[CH:22]=[N:23][N:24]([CH2:26][CH2:27][OH:28])[CH:25]=5)[CH:19]=[CH:20][C:15]4=[N:14][CH:13]=3)[CH3:11])[CH:7]=[CH:6][C:5]2=[N:1][CH:2]=1

Participants

6

Reactant 3

HCID 312751,4-DioxaneHCID 67184N-bromobutanimideHCID 69077928HCID 69077928, compound

Product 1

HCID 57917324HCID 57917324, compound

Reagents, catalysts & solvents 2

HCID 313Hydrochloric AcidSolventHCID 6344DichloromethaneSolvent2×

Procedure

(rac)-3-(1-Imidazo[1,2-a]pyridin-6-yl-ethyl)-6-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazol-4-yl}-imidazo[1,2-b]pyridazine (obtained by analogy of Stage 185.1 by replacing (rac)-6-chloro-3-[1-(3-methyl-3H-benzoimidazol-5-yl)-ethyl]-imidazo[1,2-b]pyridazine with (rac)-6-chloro-3-(1-imidazo[1,2-a]pyridin-6-yl-ethyl)-imidazo[1,2-b]pyridazine (Example 292), 150 mg, 0.328 mmol) was dissolved in DCM (3.3 mL) and NBS (64.2 mg, 0.984 mmol) was added. It was stirred at rt for 3 h then the solvent was removed. The residue was purified by flash chromatography (CombiFlash® Companion System®, with RediSep® silica gel column, 0 to 20% MeOH in DCM). Combined fractions were concentrated and dissolved in DCM (1 mL) with 4 N HCl in dioxane (0.246 mL, 0.984 mmol). The RM was stirred at rt for 2 min. The solvent was removed and the residue was purified by preparative HPLC with acetonitrile and water (+0.1% TFA). The fractions were joined and acetonitrile was removed. The aqueous solution was basified with 5% NaHCO3 solution and was extracted with EtOAc twice. Combined organic layers was washed with brine and dried over Na2SO4. It was filtered to afford after evaporation of the solvent the title compound as a white solid (tR 0.7 min (conditions 2), MH+=452, 1H-NMR in DMSO-d6: 8.46 (s, 1H); 8.40 (s, 1H); 8.04 (m, 2H); 7.78 (s, 1H); 7.67 (s, 1H); 7.52 (m, 2H); 7.33 (d, 1H); 4.95 (t, 1H); 4.76 (q, 1H); 4.18 (t, 2H); 3.75 (q, 2H); 1.80 (d, 3H)).

Workup

  1. customthe solvent was removed
  2. customThe residue was purified by flash chromatography (CombiFlash® Companion System®, with RediSep® silica gel column, 0 to 20% MeOH in DCM)
  3. concentrationCombined fractions were concentrated
  4. stirringThe RM was stirred at rt for 2 min
  5. customThe solvent was removed
  6. customthe residue was purified by preparative HPLC with acetonitrile and water (+0.1% TFA)
  7. customacetonitrile was removed
  8. extractionwas extracted with EtOAc twice
  9. washCombined organic layers was washed with brine
  10. dry with materialdried over Na2SO4
  11. filtrationIt was filtered
  12. customto afford
  13. customafter evaporation of the solvent the title compound as a white solid (tR 0.7 min (conditions 2), MH+=452, 1H-NMR in DMSO-d6: 8.46 (s, 1H); 8.40 (s, 1H); 8.04 (m, 2H); 7.78 (s, 1H); 7.67 (s, 1H); 7.52 (m, 2H); 7.33 (d, 1H); 4.95 (t, 1H); 4.76 (q, 1H); 4.18 (t, 2H); 3.75 (q, 2H); 1.80 (d, 3H))

Sources & evidence

ORD record
ord-526fe69989e64a7f86947551e9becf14
Source dataset
uspto-grants-2014_09
Patent number
US08822468B2

Reaction notes

Loading…